Cowen and Company’s Accelerate Diagnostics AXDX Stock Holding History

Cowen and Company’s Portfolio AXDX Stock Details AXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-1,820	Closed	-$338K	–	465
2019 Q3	$338K	Buy	+1,820	New	+$352K	0.09%	181

Other funds holding AXDX

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

Cowen and Company's AXDX Position: Q4 2019 in Review

Cowen and Company sold out of Accelerate Diagnostics (AXDX) in Q4 2019, closing a stake of 1,820 shares — an estimated $338K sold.

Cowen and Company first reported a position in AXDX in Q3 2019 and held it in 1 quarter. The position peaked at $338K in Q3 2019. 109 funds tracked by Wall St. Rank hold AXDX as of Q4 2019.

Cowen and Company reported no remaining Accelerate Diagnostics position as of Q4 2019 after selling out during the quarter.
Cowen and Company sold 1,820 Accelerate Diagnostics shares in Q4 2019, an estimated $338K.
Cowen and Company first reported a position in Accelerate Diagnostics in Q3 2019 and held it in 1 quarter.
Cowen and Company's Accelerate Diagnostics position peaked at $338K in Q3 2019.
109 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q4 2019.

Based on Cowen and Company's 13F filing for Q4 2019, filed 11 Feb 2020.